1-(2-deoxy-β-D-lyxofuranosyl)-5-bromouracil | 1251825-18-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(2-deoxy-β-D-lyxofuranosyl)-5-bromouracil
• 英文别名: 5-bromo-1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione；5-bromo-1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 1251825-18-9
• 化学式: C₉H₁₁BrN₂O₅
• 分子量: 307.101
• InChiKey: WOVKYSAHUYNSMH-FSDSQADBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 溶剂黄146 作用下， 以 水 为溶剂， 反应 0.5h， 生成 1-(2-deoxy-β-D-lyxofuranosyl)-5-bromouracil
  参考文献：
  名称：

  各种1-（2'-脱氧-β-d-呋喃糖基），1-（2'-氟-β-d-木呋喃糖基），1-（3'-氟-β-d-阿拉伯呋喃糖基）和2'-Fluoro-2'，3'-didehydro-2'，3'-dideoxyribose嘧啶核苷类似物抗鸭乙型肝炎病毒（DHBV）和人乙型肝炎病毒（HBV）复制

  摘要：

  尽管存在成功的疫苗和抗病毒疗法，但乙型肝炎病毒（HBV）的感染仍然是急性和慢性肝病以及高死亡率的全球主要原因。我们合成并评估了几种lyxofuranosyl，2'-fluorooxylofuranosyl，3'-fluoroarabinofuranosyl和2'-fluoro-2'，3'-didehydro-2'，3'-dideoxyribose嘧啶核苷类似物对乙型肝炎病毒的抗病毒活性。在所检查的化合物中，1-（2-脱氧-β - d-呋喃呋喃糖基）胸腺嘧啶（23），1-（2-脱氧-β - d-呋喃呋喃糖基）-5-三氟甲基尿嘧啶（25），1-（2-脱氧-2-氟-β - d-木呋喃糖基）尿嘧啶（38），1-（2-脱氧-2-氟-β- d-二呋喃呋喃糖基）胸腺嘧啶（39），2'，3'-二脱氧-2'，3'-二脱氢-2'-氟胸苷（48）和2'，3'-二脱氧-2'，3'-二脱氢-2在原代鸭肝细胞中发现'

  DOI：

  10.1021/jm100803c

文献信息

• 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
  申请人：Institut Univ. de Ciència i Tecnologia, S.A.

  公开号：EP2711007A1

  公开（公告）日：2014-03-26

  The present invention relates to the field of biotechnology. The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidine, i.e. a compound of formula (I) for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention also relates to a combination of a compound of formula (I) with at least one further compound for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or the combination.

  本发明涉及生物技术领域。本发明涉及 4-氨基吡唑并[3,4-d]嘧啶，即用于治疗或预防原发性和转移性乳腺癌和前列腺癌的式 (I) 化合物。本发明还涉及一种式（I）化合物与至少另一种化合物的组合物，用于治疗或预防原发性和转移性乳腺癌和前列腺癌。本发明还涉及一种包含式（I）化合物或组合物的药物组合物。
• SUGIMOTO, NOBUESI;XOSOGAI, MITSUO
  作者：SUGIMOTO, NOBUESI、XOSOGAI, MITSUO

  DOI：——

  日期：——
• MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE
  申请人：Angiotech Pharmaceuticals (US), Inc.

  公开号：US20130289235A1

  公开（公告）日：2013-10-31

  Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.
• COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS
  申请人：Angiotech International AG

  公开号：US20140328891A1

  公开（公告）日：2014-11-06

  Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.
• US7238795B2
  申请人：——

  公开号：US7238795B2

  公开（公告）日：2007-07-03